๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity โ—† Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing โ—† Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich โ—† Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery โ—† Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma โ—† Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide โ—† The โ‚ฌ100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany โ—† Ireland's โ‚ฌ93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact โ—† Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity โ—† Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing โ—† Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich โ—† Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery โ—† Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma โ—† Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide โ—† The โ‚ฌ100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany โ—† Ireland's โ‚ฌ93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact โ—†
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hefei
Clinical trial register · China

Clinical Trials in Hefei, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 44 Guangzhou 29 Shanghai 25 Tianjin 22 Hangzhou 20
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing44 Guangzhou29 Shanghai25 Tianjin22 Hangzhou20
All 57 locations
Target enrolment
to

Trials with a site in Hefei

5 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
NCT07569757Multiple Myeloma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
260
Bengbu, Hefei, Beijing, Chongqing, Lanzhou, Guangzhou, Zhanjiang, Nanning
2026-06
Active, closed
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
NCT05827016Multiple Myeloma
Bristol-Myers Squibb
Phase 3
1,230
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Zhengzhou, Changsha, Nanjing
2023-06-22
Recruiting
Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
NCT05294055Multiple Myeloma, Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
120
Hefei, Beijing, Zhengzhou, Jinan, Tianjin
2022-04-26
Not yet open
A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)
NCT05181501Multiple Myeloma
Nanjing IASO Biotechnology Co., Ltd.
Phase 1
20
Hefei, Changzhou, Nanjing
2022-04
Active, closed
A Study of NINLAROยฎ in Chinese Adults With Multiple Myeloma
NCT05013190Multiple Myeloma
Takeda
Observational
72
Hefei, Beijing, Zhengzhou, Hohhot, Suzhou, Nanchang, Shenyang, Qingdao
2021-10-29
Rows per page Showing 1–5 of 5
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-china/city/hefei

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5 of those studies with a site in Hefei that also match the filters currently applied.

How many clinical trials are recruiting in Hefei?

1 of the 5 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hefei), 5 studies
PhaseStudiesRecruitingShare
Phase 32040%
Observational1020%
Phase 11020%
Phase 21120%

Most active sponsors

Lead sponsors with the most studies (Hefei)
Lead sponsorStudiesRecruiting
Bristol-Myers Squibb10
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.10
Institute of Hematology & Blood Diseases Hospital, China11
Nanjing IASO Biotechnology Co., Ltd.10
Takeda10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.